Agilent Technologies Stock News

Fear at extremes: Investor and consumer sentiment is near historic lows, signaling a high-probability buying opportunity, historically followed by strong 12-month gains. Economic reality check: Real-time economic indicators show GDP growth of more than 2%, despite widespread recession fears, highlighting a disconnect between sentiment and fundamentals. Inflation truth vs. hype: Real-time data s...

SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE: A) is pleased to announce its role in supporting Autolus Therapeutics' FDA approval for AUCATZYL®, a recently approved CAR T therapy. Agilent's advanced cell analysis instrumentation, specifically the xCELLigence Real-Time Cell Analysis (RTCA) technology, was applied in developing and validating AUCATZYL. The xCELLigence RTC...

SANTA CLARA, Calif.--(BUSINESS WIRE)--Please replace the release with the following corrected version due to multiple revisions to the fifth paragraph. The updated release reads: AGILENT TO SHOWCASE NEXT-GENERATION DIGITAL PATHOLOGY SOLUTIONS AT USCAP 2025 Agilent Technologies Inc. (NYSE: A) is excited to announce its participation at the upcoming United States and Canadian Academy of Pathology...

SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE: A) is excited to announce its participation at the upcoming United States and Canadian Academy of Pathology (USCAP) Conference, which will be held March 22-27, 2025, in Boston. At the conference, Agilent will highlight innovative digital pathology solutions designed to enhance diagnostic accuracy and efficiency. In pathology...

SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE: A) today announced that Columbia University has received an Agilent Research Catalyst (ARC) Award on behalf of Dr. Pawel Muranski, an internationally recognized researcher and physician-scientist specializing in bone marrow transplant (BMT) and cancer cellular immunotherapy. Dr. Muranski is the Director of Cellular Immunothe...

SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE: A) today announced its PD-L1 IHC 28-8 pharmDx kit has received two new companion diagnostic indications approvals under EU IVDR1, expanding the eligibility of treatment to early-stage non-small cell lung cancer (NSCLC) and previously untreated advanced melanoma patients. These two new indications bring the total indications ...

Agilent Technologies, Inc. (NYSE:A ) TD Cowen 45th Annual Healthcare Conference Call March 4, 2025 9:50 AM ET Company Participants Padraig McDonnell - Chief Executive Officer Bob McMahon - Chief Financial Officer Conference Call Participants Daniel Brennan - TD Cowen Daniel Brennan Alright, good. I guess we'll start in a minute or two early here, great day two of the TD Cowen Global Healthcare ...

Agilent Technologies, a leader in life sciences and diagnostics, has a market cap of $38B and a 10-year CAGR of 13.6%. Key financial metrics: consistent revenue growth, stable gross profit margin above 50%, and a robust return on invested capital, despite some fluctuations. The stock fell too far after its recent earnings report, making it too good to pass up at its current level.